Vorsitz: K.-H. Kuck (Hamburg), B. Schumacher (Bad Kissingen)
| (V1559) | Myeloperoxidase plasma levels predict thromboembolic stroke in patients with atrial fibrillation |
| D. Steven, M. Wösten, Y. Kohsar, T. Rudolph, I. Drewitz, B. A. Hoffmann, T. Rostock, T. Meinertz, S. Willems, S. Baldus, V. Rudolph (Hamburg) | |
| (V1560) | Atrial and Brain Natriuretic Peptide Secretion After Percutaneous Closure of the Left Atrial Appendage |
| N. Majunke, V. Adams, I. Dähnert, N. Mangner, G. C. Schuler, S. Möbius-Winkler (Leipzig) | |
| (V1561) | LAA Closure Therapy with the WATCHMAN Device in Patients with Contraindications to Warfarin: Results from the “ASA Plavix Registry” (ASAP) |
| P. Sick, V. Reddy, H. Sievert, N. Wunderlich, P. Neuzil, S. Möbius-Winkler, G. C. Schuler (Regensburg, Frankfurt am Main, Leipzig; New York, US; Prag, CZ) | |
| (V1562) | Left Atrial Appendage Occlusion with the Watchman Device: Which Postimplant Anticoagulation Regime is Necessary? First Results of the LAOTSE Trial |
| A. Langbein, A. Schade, G. Groschup, J. Krug, V. Ziegler, H. Soda, B. Schumacher (Bad Neustadt a. d. Saale) | |
| (V1563) | Long-term Outcome of Percutaneous Closure of the Left Atrial Appendage with the Watchman Device |
| N. Majunke, I. Dähnert, P. Sick, N. Mangner, G. C. Schuler, S. Möbius-Winkler (Leipzig, Regensburg) | |
| (V1564) | Stroke Prevention in Non-valvular Atrial Fibrillation: Long-Term Results after 6 Years of the WATCHMAN Left Atrial Appendage Occlusion Pilot Study |
| P. Sick, Z. G. Turi, E. Grube, G. C. Schuler, K. E. Hauptmann, G. Mishkel, S. J. Yakubov, S. Almany, D. Holmes (Regensburg, Essen, Leipzig, Trier; New Jersey, Springfield, Columbus, Michigan, Rochester, US) |